Monocyte subsets study in children with Mycoplasma pneumoniae pneumonia

Zhihua Wang1, Lei Yang2, Jing Ye1,3

  • 1Tianjin Hospital of Integrated Traditional Chinese and Western Medicine, Tianjin Nankai Hospital, Tianjin, China.

Immunologic Research
|November 28, 2019
PubMed

Insights

Pediatric Mycoplasma pneumoniae (MP) pneumonia is linked to increased intermediate and non-classical monocytes. Lower human leukocyte antigen-DR (HLA-DR) expression on intermediate monocytes may indicate disease severity.

Area of Science:

  • Immunology
  • Pediatric Infectious Diseases

Background:

  • Monocytes play a crucial role in immune responses.
  • Mycoplasma pneumoniae (MP) pneumonia is a common respiratory infection in children.
  • Understanding monocyte subset dynamics in MP pneumonia is essential for diagnosis and prognosis.

Purpose of the Study:

  • To investigate changes in monocyte subsets (classical, intermediate, non-classical) and human leukocyte antigen-DR (HLA-DR) expression during pediatric MP pneumonia.
  • To correlate these changes with disease severity and clinical outcomes.

Main Methods:

  • Flow cytometry was used to analyze monocyte subsets (CD14+CD16-, CD14brightCD16+, CD14dimCD16+) in healthy children and MP pneumonia patients.
  • HLA-DR expression on monocyte subsets was quantified at admission and remission stages.
  • Patients were categorized into severe and non-severe groups.

Main Results:

  • MP pneumonia patients exhibited higher proportions of intermediate and non-classical monocytes compared to healthy controls.
  • Monocyte subset proportions decreased at remission compared to admission.
  • The intermediate monocyte subset showed higher HLA-DR expression at admission.
  • Lower HLA-DR expression on intermediate monocytes was observed in severe MP pneumonia cases.

Conclusions:

  • Pediatric MP pneumonia is associated with an increased proportion of non-classical and intermediate monocytes, suggesting their involvement in the disease's pathogenesis.
  • Decreased HLA-DR expression on intermediate monocytes (CD14brightCD16+) may serve as a potential biomarker for MP pneumonia severity in children.